More Details Emerge on Biogen’s Alzheimer’s Comeback

Earlier this week, Biogen stunned everyone by announcing that analysis of a large dataset from several of its clinical trials of aducanumab in Alzheimer’s patients were positive. This came after an announcement in March that the company and its collaboration partner, Tokyo-based Eisai, were basically abandoning the program after an independent data monitoring committee indicated the trials probably wouldn’t hit their primary endpoint.

Reuters reports that the turnaround was built on “top secret” meetings, non-disclosure agreements and six months of researchers, regulators and statisticians churning the data on a larger dataset that included a total of 3,285 patients.